Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926875 | 1.00 | MEN1 (0.42) | MEN1KMT2AMAPK1MAPTL3MBTL1 | |
| SCHEMBL1586513 | 0.90 | HPGD (0.35) | MEN1KMT2AMAPK1MAPTL3MBTL1 | |
| SCHEMBL11926877 | 0.90 | HPGD (0.35) | MEN1KMT2AMAPK1MAPTL3MBTL1 | |
| SCHEMBL27867351 | 0.83 | MEN1 (0.42) | MEN1KMT2AMAPK1L3MBTL1ALOX15 | |
| SCHEMBL1586222 | 0.79 | L3MBTL1 (0.32) | MAPTL3MBTL1HPGD | |
| SCHEMBL11926878 | 0.79 | L3MBTL1 (0.32) | MAPTL3MBTL1HPGD | |
| SCHEMBL1586523 | 0.79 | MEN1 (0.52) | MEN1KMT2AMAPK1MAPTALOX15 | |
| SCHEMBL11926873 | 0.77 | SLC9A1 (0.50) | MEN1KMT2AMAPK1MAPTL3MBTL1 | |
| SCHEMBL1586579 | 0.77 | SLC9A1 (0.50) | MEN1KMT2AMAPK1MAPTL3MBTL1 | |
| SCHEMBL27867350 | 0.74 | HTR2C (0.40) | MEN1KMT2AMAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488501-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8357635-B2 | Microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-01-22 | — | — | US | disclosed |
| EP-2488501-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202867-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045355-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202867-A1 | NOVEL MICROBIOCIDES | CD14, FPR1, MPO | MEN1 3185/4885KMT2A 4264/4885MAPK1 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.